Oncolytics Biotech Inc.ONCYNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank93
3Y CAGR+112.4%
5Y CAGR+28.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+112.4%/yr
Annual compound
5Y CAGR
+28.9%/yr
Recent acceleration
Percentile
P93
Near historical high
vs 5Y Ago
3.6x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2024 | 64.98% |
| 2023 | 10.69% |
| 2022 | 15.02% |
| 2021 | 6.79% |
| 2020 | -13.33% |
| 2019 | 18.23% |
| 2018 | 0.27% |
| 2017 | -3.86% |
| 2016 | 13.58% |
| 2015 | -37.78% |